
Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma
Oncolytic VirusDiffuse Intrinsic Pontine Glioma1 moreThis is a single-arm, single-center, drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in progressive DIPG patients (NCI-CTCAE V5.0).

Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)
SegmentectomyLung AdenocarcinomaThis is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1012. The goal of this clinical trial is to confirm the theraputic effect of segmentectomy for ground glass-dominant invasive lung cancer with size of 2-3cm. The main questions it aims to answer are: The 5-year disease-free survival of patients having ground glass-dominant invasive lung cancer with size of 2-3cm; The post-operative lung function tests after receiving segmentectomy. Participants will receive segmentectomy as the surgical procedure.

IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
Advanced Solid TumorNon-small Cell Lung Cancer4 moreThis is a multi-center, open-label, dose-escalation and cohort-expansion phase I clinical study to evaluate the safety and tolerability, pharmacokinetics profile, efficacy and immunogenicity of IMM2520 in subjects with advanced solid tumors.

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor...
Advanced Biliary Tract CancerThe objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus lenvatinib in patients with Immune Checkpoint Inhibitor previously treated advanced biliary tract cancer (BTC).

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal...
Metastatic Colorectal CancerThe purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer). All patients included must have metastatic bowel cancer and receive or have received at least two lines of standard chemotherapy. The cancer must not be available for surgery with curative intent.

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Head and Neck Squamous Cell CarcinomaHead and Neck Cancer2 moreThis research study is evaluating effectiveness and safety of a combination of immunotherapy drug, pembrolizumab, with chemotherapy, as a possible treatment before and after surgery for squamous cell carcinoma of the head and neck (HNSCC). The combination of pembrolizumab and chemotherapy will be given prior to your surgery, while immunotherapy pembrolizumab will be continued for approximately 1 year after surgery. The names of the study drugs involved in this research study are: pembrolizumab (a type of immunotherapy) docetaxel (a type of chemotherapy) cisplatin (a type of chemotherapy) carboplatin (a type of chemotherapy)

With Love, Grandma ("Con Cariño, Abuelita") Pilot Study
CancerBreast9 moreThe purpose of this study is to assess the feasibility, acceptability, and preliminary effects of a digital (web and mobile-phone-based) program to improve lifestyle behaviors (physical activity, dietary intake) among Hispanic female cancer survivors and adult daughters.

A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
Myelodysplastic SyndromesAcute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts1 moreThe goal of this interventional study is to evaluate if pre-emptive intervention using Azacitidine and / or donor lymphocytes or tapering of immune suppression in measurable residual disease (MRD) positive subjects can prevent clinical relapse. Participants will undergo MRD surveillance and be subjected to intervention in case of MRD positivity. Results will be compared with NMDSG14B, part one, in which MRD was analyzed in included patients without recieving intervention.

Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma...
CD20-positive B-cell Non-Hodgkin's LymphomaThis is a Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of IMM0306 in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL).

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
HNSCCOpen-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients will be randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to receive pembrolizumab alone.